INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21301, 'Aminosalicylic acid', 'Tioguanine', 'Moderate', 'The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.', 'DDInter', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.', 'Synergism', 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21316/', '', 'Capreomycin, Rifamycin, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Pyridoxine, Pretomanid', 'Fluorouracil, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21302, 'Aminosalicylic acid', 'Trabectedin', 'Moderate', 'Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.', 'DDInter', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.', 'Synergism', 'The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21317/', '', 'Capreomycin, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid', 'Vincristine, Cabazitaxel, Vinblastine, Paclitaxel, Topotecan, Teniposide, Irinotecan, Vinorelbine, Etoposide, Docetaxel', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21303, 'Aminosalicylic acid', 'Typhoid vaccine (live)', 'Major', 'INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.', 'DDInter', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.', 'Others', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21318/', '', 'Pyridoxine, Pretomanid', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21304, 'Amiodarone', 'Abarelix', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21319/', '', 'Exemestane, Fulvestrant, Aminoglutethimide, Letrozole', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21305, 'Amiodarone', 'Aminolevulinic acid', 'Major', 'Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.', 'DDInter', 'Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John''s wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.', 'Synergism', 'Photosensitizing agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21320/', '', 'Pertuzumab, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Aflibercept, Trastuzumab, Hydroxyurea, Talimogene laherparepvec, Estramustine, More', 'Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21306, 'Amiodarone', 'Aminophylline', 'Moderate', 'Amiodarone may decrease the hepatic metabolism of theophylline. Increased theophylline serum concentrations may result. Patients with chronic obstructive pulmonary disease, congestive heart failure, or cirrhosis may have slower theophylline clearance rates; therefore, they may be at greater risk of developing theophylline toxicity.', 'DDInter', 'If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended. An interaction may not become apparent for several weeks. Patients should be advised to notify their physician if they experience any signs of theophylline toxicity including nausea, vomiting, diarrhea, headache, restlessness, insomnia, seizures, or a worsening of their arrhythmia. It may be necessary to reduce theophylline dosage.', 'Metabolism', 'If these drugs are given concurrently, close clinical and laboratory monitoring of response and tolerance is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21321/', '', 'Quinidine, Dronedarone, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Ibutilide', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Dyphylline, Mepolizumab, Bromotheophylline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21307, 'Amisulpride', 'Amiodarone', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21322/', '', 'Lidocaine, Moricizine, Mexiletine, Tocainide', 'Brexpiprazole, Loxapine, Molindone, Thiothixene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21308, 'Amitriptyline', 'Amiodarone', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21323/', '', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Esketamine', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21309, 'Amoxapine', 'Amiodarone', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21324/', '', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Esketamine', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21310, 'Amphotericin B (cholesteryl sulfate)', 'Amiodarone', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21325/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21311, 'Amphotericin B (lipid complex)', 'Amiodarone', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21326/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21312, 'Amphotericin B (liposomal)', 'Amiodarone', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21327/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21313, 'Amprenavir', 'Amiodarone', 'Major', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may significantly increase the plasma concentrations of antiarrhythmic agents that are primarily metabolized by CYP450 3A4 such as amiodarone, bepridil, systemic lidocaine, and quinidine. The proposed mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by amprenavir. The interaction has not been specifically studied, but could conceivably lead to serious and/or life-threatening reactions including cardiac arrhythmias and other toxicities if levels are substantially increased. The use of amiodarone, bepridil, and quinidine has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.', 'DDInter', 'Caution is advised if amprenavir or fosamprenavir must be used with antiarrhythmic agents that are substrates of CYP450 3A4. Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever amprenavir or fosamprenavir is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary. Concomitant use with amiodarone, bepridil, lidocaine, or quinidine is specifically contraindicated according to Canadian and European labeling.', 'Metabolism', 'Caution is advised if amprenavir or fosamprenavir must be used with antiarrhythmic agents that are substrates of CYP450 3A4.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21328/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Elbasvir, More', 'Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21314, 'Anagrelide', 'Amiodarone', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21329/', '', 'Pertuzumab, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Aflibercept, Trastuzumab, Hydroxyurea, Talimogene laherparepvec, Estramustine, More', 'Tocainide, Moricizine, Bretylium', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21315, 'Anakinra', 'Amiodarone', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21330/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More', 'Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21316, 'Anisindione', 'Amiodarone', 'Major', 'Amiodarone may increase the pharmacologic effects of warfarin by inhibiting CYP450 2C9 hepatic metabolism of S-warfarin. Similar effects may also occur with other oral anticoagulants, resulting in significant hypoprothrombinemia and bleeding. When amiodarone is added to an anticoagulant regimen, increased anticoagulant effects may become apparent within one to several weeks and may persist for months after the amiodarone is discontinued. The effects of this interaction are highly variable - while some patients are asymptomatic, serious and life-threatening bleeding complications have been reported in others. Patients who are poor CYP450 2C9 metabolizers may have a higher risk of bleeding and a faster onset of the interaction.', 'DDInter', 'An empiric 30% to 50% reduction in anticoagulant dosage has been recommended, in addition to frequent monitoring of the patient and the prothrombin time or International Normalized Ratio (INR). Patients should be advised to notify their physician promptly if they experience any signs of excessive anticoagulation such as unusual or prolonged bleeding, bruising, vomiting, change in stool or urine color, headache, dizziness, or weakness.', 'Metabolism', 'An empiric 30% to 50% reduction in anticoagulant dosage has been recommended, in addition to frequent monitoring of the patient and the prothrombin time or International Normalized Ratio (INR).', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21331/', '', 'Lidocaine, Tocainide, Procainamide, Flecainide, Mexiletine, Dofetilide, Bretylium, Ibutilide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21317, 'Amiodarone', 'Apalutamide', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21332/', '', 'Moricizine, Tocainide, Bretylium, Mexiletine', 'Exemestane, Fulvestrant, Aminoglutethimide, Letrozole', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21318, 'Amiodarone', 'Apixaban', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp. However, caution may be advisable. Closer monitoring of the pharmacologic effects of apixaban may be appropriate whenever a CYP450 3A4 or P-gp inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'No dosage adjustment for apixaban is required during concomitant therapy with lone inhibitors of CYP450 3A4 or P-gp, or moderate or weak dual inhibitors of both CYP450 3A4 and P-gp.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21333/', '', 'Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Iloprost, Lepirudin, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21319, 'Amiodarone', 'Apomorphine', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21334/', '', 'Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Trospium, Acetohydroxamic acid, Yohimbine, Flavoxate, Avanafil, Phenyl salicylate, Ammonium chloride, More', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21320, 'Amiodarone', 'Aprepitant', 'Moderate', 'Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.', 'DDInter', 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21335/', '', 'Scopolamine, Nabilone, Rolapitant, Dronabinol', 'Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21321, 'Amiodarone', 'Arbutamine', 'Major', 'Arbutamine may precipitate or exacerbate supraventricular or ventricular arrhythmias due to its sympathomimetic effects.', 'DDInter', 'The manufacturer recommends that arbutamine not be given concurrently with proarrhythmic drugs.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21336/', '', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Phenylephrine, Metaraminol, Dopamine, More', 'Dofetilide, Dronedarone, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21322, 'Amiodarone', 'Arformoterol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', 'DDInter', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21337/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21323, 'Amiodarone', 'Aripiprazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of aripiprazole, which is primarily metabolized by these isoenzymes.', 'DDInter', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 and/or 2D6 inhibitor is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary. The manufacturer recommends that aripiprazole dosage be reduced to one-half the normal dosage during concomitant administration with ketoconazole or quinidine, and additional dosage adjustments be made based on clinical evaluation.', 'Metabolism', 'Pharmacologic response to aripiprazole should be monitored more closely whenever a CYP450 3A4 and/or 2D6 inhibitor is added to or withdrawn from therapy, and the aripiprazole dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21338/', '', 'Moricizine, Tocainide, Bretylium, Mexiletine', 'Brexpiprazole, Loxapine, Molindone, Thiothixene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21324, 'Amiodarone', 'Armodafinil', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme. Conversely, the plasma levels of some of these inhibitors may decrease, since many of them are also substrates of CYP450 3A4, and modafinil and armodafinil have been found to be modest inducers of CYP450 3A4. The clinical significance of this potential interaction is unknown. Clinical monitoring for altered effects of modafinil and armodafinil as well as the CYP450 3A4 inhibitor may be appropriate following addition or withdrawal of one or the other drug.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21339/', '', 'Propafenone, Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 'Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21325, 'Amiodarone', 'Arsenic trioxide', 'Major', 'Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'If possible, medications that are known to prolong the QT interval should be discontinued prior to initiating therapy with arsenic trioxide and withheld for at least several weeks after completion of therapy. Caution is advised if concomitant use cannot be avoided. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. An absolute QT interval exceeding 500 msec will require immediate action to correct concomitant risk factors, if any, as well as a thorough assessment of the need for continued therapy. Patients who develop syncope or arrhythmia should be hospitalized for clinical and laboratory monitoring.', 'Synergism', 'If possible, medications that are known to prolong the QT interval should be discontinued prior to initiating therapy with arsenic trioxide and withheld for at least several weeks after completion of therapy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21340/', '', 'Lidocaine, Moricizine, Bretylium, Tocainide', 'Pertuzumab, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Aflibercept, Trastuzumab, Hydroxyurea, Talimogene laherparepvec, Estramustine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21326, 'Amiodarone', 'Asenapine', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21341/', '', 'Lidocaine, Moricizine, Bretylium, Tocainide', 'Brexpiprazole, Loxapine, Molindone, Thiothixene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21327, 'Amiodarone', 'Asparaginase Erwinia chrysanthemi', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'DDInter', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21342/', '', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21328, 'Amiodarone', 'Asparaginase Escherichia coli', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'DDInter', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21343/', '', 'Pertuzumab, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Aflibercept, Trastuzumab, Hydroxyurea, Talimogene laherparepvec, Estramustine, More', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21329, 'Amiodarone', 'Astemizole', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21344/', '', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, More', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21330, 'Amiodarone', 'Atazanavir', 'Moderate', 'Coadministration with atazanavir may increase the plasma concentrations of amiodarone, systemic lidocaine, and quinidine. The proposed mechanism is atazanavir inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of these antiarrhythmic agents. The interaction has not been studied but could conceivably lead to serious and/or life-threatening reactions including cardiac arrhythmias and other toxicities.', 'DDInter', 'Caution is advised if atazanavir must be used with amiodarone, systemic lidocaine, or quinidine. Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever atazanavir is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary. According to some authorities, use of the fixed combination atazanavir-cobicistat with these antiarrhythmic agents is considered contraindicated.', 'Metabolism', 'Caution is advised if atazanavir must be used with amiodarone, systemic lidocaine, or quinidine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21345/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Elbasvir, More', 'Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21331, 'Amiodarone', 'Atenolol', 'Moderate', 'Additive effects of severe bradycardia, cardiac arrest, and ventricular fibrillation may occur in patients administered amiodarone and beta blockers. The mechanism may be related to additive slowing in AV conduction.', 'DDInter', 'Clinical monitoring of patient hemodynamic status and response is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21346/', '', 'Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21332, 'Amiodarone', 'Atomoxetine', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21347/', '', 'Amphetamine, Pemoline, Metamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21333, 'Amiodarone', 'Atorvastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21348/', '', 'Bempedoic acid, Fenofibric acid, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Alirocumab', 'Propafenone, Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21334, 'Amiodarone', 'Auranofin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21349/', '', 'Penicillamine', 'Quinidine, Propafenone, Dronedarone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21335, 'Amiodarone', 'Aurothioglucose', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21350/', '', 'Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, More', 'Penicillamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21336, 'Amiodarone', 'Avapritinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of avapritinib, which has been shown in vitro to be primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9.', 'DDInter', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as intracranial hemorrhage, cognitive impairment, mood disorders, hallucinations, edema, and decreases in hemoglobin, leukocytes, neutrophils and platelets, and the dosing of avapritinib adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when avapritinib is used concomitantly with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21351/', '', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Regorafenib, Copanlisib, Alpelisib, Abemaciclib, Erdafitinib, Neratinib, Trametinib, Capmatinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21337, 'Amiodarone', 'Axitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of axitinib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors. Alternative agents with no or minimal CYP450 3A4 inhibition potential are recommended whenever possible. Otherwise, patients should be monitored closely for development of toxicity such as hypertension/hypertensive crisis, arterial and venous thromboembolic complications, hemorrhage, gastrointestinal perforation or fistula, thyroid dysfunction, reversible posterior leukoencephalopathy syndrome, proteinuria, and liver enzyme elevations or hepatic impairment.', 'Metabolism', 'Caution is advised if axitinib is prescribed with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21352/', '', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Regorafenib, Copanlisib, Alpelisib, Abemaciclib, Erdafitinib, Neratinib, Trametinib, Capmatinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21338, 'Amiodarone', 'Azithromycin', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Coadministration with other agents that can prolong the QT interval such as macrolide antibiotics may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). Some macrolides such as clarithromycin, erythromycin, and troleandomycin are also potent inhibitors of CYP450 3A4 and may significantly inhibit the metabolism of amiodarone, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The concurrent use of amiodarone with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if these agents are prescribed together, especially to patients with underlying risk factors. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism, Synergism', 'The concurrent use of amiodarone with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21353/', '', 'Tetracycline, Cefixime, Tetracycline, Ganciclovir, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, Polymyxin B, Famciclovir, Sulfamethizole, More', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21339, 'Amiodarone', 'Bedaquiline', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21354/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21340, 'Amiodarone', 'Bendamustine', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of bendamustine, which has been shown in vitro to be metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if bendamustine is used in combination with CYP450 1A2 inhibitors. Close monitoring for toxicity (e.g., neutropenia, thrombocytopenia, anemia, leukopenia, infections, bleeding complications) is recommended, and the bendamustine dosage adjusted as necessary.', 'Metabolism', 'Caution is advised if bendamustine is used in combination with CYP450 1A2 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21355/', '', 'Quinidine, Lidocaine, Dronedarone, Tocainide, Procainamide, Flecainide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Temozolomide, Thiotepa, Carmustine, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Melphalan, Ifosfamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21341, 'Amiodarone', 'Bendroflumethiazide', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21356/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21342, 'Amiodarone', 'Benznidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21357/', '', 'Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, More', 'Miltefosine, Nifurtimox', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21343, 'Amiodarone', 'Benzthiazide', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21358/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21344, 'Amiodarone', 'Bepridil', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21359/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21345, 'Amiodarone', 'Betaxolol', 'Moderate', 'Additive effects of severe bradycardia, cardiac arrest, and ventricular fibrillation may occur in patients administered amiodarone and beta blockers. The mechanism may be related to additive slowing in AV conduction.', 'DDInter', 'Clinical monitoring of patient hemodynamic status and response is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21360/', '', 'Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Guanethidine, Levobunolol', 'Propafenone, Procainamide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21346, 'Amiodarone', 'Betaxolol (ophthalmic)', 'Moderate', 'Additive effects of severe bradycardia, cardiac arrest, and ventricular fibrillation may occur in patients administered amiodarone and beta blockers. The mechanism may be related to additive slowing in AV conduction.', 'DDInter', 'Clinical monitoring of patient hemodynamic status and response is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21361/', '', 'Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Guanethidine, Levobunolol', 'Quinidine, Lidocaine, Propafenone, Procainamide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21347, 'Amiodarone', 'Betrixaban', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the plasma concentrations of betrixaban, which is a substrate of the efflux transporter. In the Acute Medically Ill Prevention with Extended Duration Betrixaban (APEX) Study, use of betrixaban at a 50% dosage reduction in combination with P-gp inhibitors or in the presence of severe renal impairment was associated with increased relative risks of bleeding, including major bleeding, compared to treatment with enoxaparin.', 'DDInter', 'When used with P-gp inhibitors, the recommended dosage of betrixaban is an initial single dose of 80 mg followed by 40 mg once daily. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women).', 'Others', 'When used with P-gp inhibitors, the recommended dosage of betrixaban is an initial single dose of 80 mg followed by 40 mg once daily.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21362/', '', 'Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Iloprost, Lepirudin, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21348, 'Amiodarone', 'Bicalutamide', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21363/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Exemestane, Fulvestrant, Aminoglutethimide, Letrozole, Megestrol acetate, Ethinylestradiol, Diethylstilbestrol, Medroxyprogesterone acetate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21349, 'Amiodarone', 'Binimetinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp), uridine diphosphate glucuronosyltransferase (UGT) 1A1 or 2B7, and/or breast cancer resistance protein (BCRP) may increase the plasma levels and risk of adverse effects of binimetinib. The proposed mechanism involves the reduced metabolic clearance of binimetinib through inhibition of P-gp, UGT 1A1, UGT 2B7, and/or BCRP.', 'DDInter', 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors. Binimetinib should be monitored more closely whenever a P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitor is added to or withdrawn from therapy, and the binimetinib dosage adjusted as necessary.', 'Metabolism', 'Until further information is available, caution is recommended if binimetinib must be used concomitantly with P-gp, UGT 1A1, UGT 2B7, and/or BCRP inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21364/', '', 'Lidocaine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Regorafenib, Copanlisib, Alpelisib, Abemaciclib, Erdafitinib, Neratinib, Trametinib, Capmatinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21350, 'Amiodarone', 'Bisacodyl', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21365/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21351, 'Amiodarone', 'Bisoprolol', 'Moderate', 'Additive effects of severe bradycardia, cardiac arrest, and ventricular fibrillation may occur in patients administered amiodarone and beta blockers. The mechanism may be related to additive slowing in AV conduction.', 'DDInter', 'Clinical monitoring of patient hemodynamic status and response is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21366/', '', 'Trandolapril, Moexipril', 'Propafenone, Procainamide, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21352, 'Amiodarone', 'Boceprevir', 'Major', 'Coadministration with the hepatitis C virus (HCV) NS3/4A protease inhibitor, boceprevir, may significantly increase the plasma concentrations of certain antiarrhythmic agents such as amiodarone, bepridil, disopyramide, and quinidine. The mechanism involves inhibition of CYP450 3A4 metabolism, as boceprevir is a potent inhibitor. The interaction has not been specifically studied, but could conceivably lead to serious and/or life-threatening reactions including cardiac arrhythmias and other toxicities if levels are significantly increased. The use of these antiarrhythmic agents has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.', 'DDInter', 'Caution is advised if boceprevir must be used with antiarrhythmic agents that are primarily metabolized by CYP450 3A4. Pharmacologic response and plasma antiarrhythmic drug levels should be monitored more closely whenever the HCV NS3/4A protease inhibitor is added to or withdrawn from therapy, and the antiarrhythmic dosage adjusted as necessary.', 'Metabolism', 'Caution is advised if boceprevir must be used with antiarrhythmic agents that are primarily metabolized by CYP450 3A4.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21367/', '', 'Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Oseltamivir, Brincidofovir, Elbasvir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21353, 'Amiodarone', 'Bortezomib', 'Moderate', 'Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.', 'DDInter', 'Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.', 'Synergism', 'Caution is advised if bortezomib is used with other neurotoxic agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21368/', '', 'Pertuzumab, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Aflibercept, Trastuzumab, Hydroxyurea, Talimogene laherparepvec, Estramustine, More', 'Propafenone, Dronedarone, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21354, 'Amiodarone', 'Bosentan', 'Moderate', 'Coadministration of bosentan with a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 may result in increased plasma concentrations of bosentan and decreased plasma concentrations of the other drug. Bosentan itself is a substrate and inducer of both CYP450 2C9 and 3A4. Theoretically, bosentan may induce metabolism of the coadministered drug while its own metabolism may be inhibited by the coadministered drug.', 'DDInter', 'When a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 is coadministered with bosentan, the possibility of diminished therapeutic response to the coadministered drug should be considered. Clinical and/or laboratory monitoring may be appropriate whenever bosentan is added to or withdrawn from therapy, and the dosage of the concomitant drug adjusted as necessary. The possibility of prolonged and/or increased pharmacologic effects of bosentan, including serious adverse effects such as hepatotoxicity, should also be considered. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. Concomitant administration of bosentan with both a potent CYP450 2C9 inhibitor (e.g., fluconazole, amiodarone) and a potent CYP450 3A4 inhibitor (e.g., ketoconazole, itraconazole, ritonavir) is not recommended. Concomitant administration with combination CYP450 2C9/3A4 inhibitors (e.g., delavirdine, imatinib, miconazole, mifepristone, voriconazole) should probably be avoided also, if possible.', 'Metabolism', 'When a drug that is both a substrate as well as inhibitor of CYP450 2C9 and/or 3A4 is coadministered with bosentan, the possibility of diminished therapeutic response to the coadministered drug should be considered.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21369/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Propafenone, Tocainide, Procainamide, Flecainide, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21355, 'Amiodarone', 'Bosutinib', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21370/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Regorafenib, Copanlisib, Alpelisib, Abemaciclib, Erdafitinib, Neratinib, Trametinib, Capmatinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21356, 'Amiodarone', 'Brentuximab vedotin', 'Moderate', 'Coadministration with potent CYP450 3A4 inhibitors or P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4 and has been found in vitro to be a substrate of the P-gp efflux transporter. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.', 'DDInter', 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.g., azole antifungal agents, clarithromycin, erythromycin, nefazodone, ritonavir, telithromycin) or P-gp inhibitors (e.g., protein kinase inhibitors, abiraterone, amiodarone, azithromycin, cyclosporine, dronedarone, ivacaftor) that are also potentially hepatotoxic. Close monitoring for adverse effects including neutropenia, infection, peripheral neuropathy, and hepatotoxicity is recommended. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.', 'Metabolism, Synergism', 'Caution is advised when brentuximab is used with potent CYP450 3A4 inhibitors (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21371/', '', 'Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Pertuzumab, Cetuximab, Avelumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, Pembrolizumab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21357, 'Amiodarone', 'Brigatinib', 'Moderate', 'Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations.', 'DDInter', 'Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever brigatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21372/', '', 'Lidocaine, Tocainide, Propafenone, Procainamide, Mexiletine, Bretylium, Ibutilide', 'Regorafenib, Copanlisib, Alpelisib, Abemaciclib, Erdafitinib, Neratinib, Trametinib, Capmatinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21358, 'Amiodarone', 'Brivaracetam', 'Minor', 'Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of brivaracetam, which is partially metabolized by the isoenzyme. The risk of a clinically relevant CYP450 2C19-mediated interaction is considered to be low according to the manufacturer.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21373/', '', 'Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, More', 'Tiagabine, Ethotoin, Topiramate, Paramethadione, Methsuximide, Perampanel, Zonisamide, Fenfluramine, Phensuximide, Methylphenobarbital, Phenacemide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21359, 'Amiodarone', 'Budesonide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4. In pharmacokinetic studies, 6- to 8-fold increases in budesonide systemic exposure (AUC) have been observed during coadministration of the potent CYP450 3A4 inhibitor ketoconazole with different oral formulations of budesonide.', 'DDInter', 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors. If concomitant use cannot be avoided, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance.', 'Metabolism', 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21374/', '', 'Propafenone, Tocainide, Procainamide, Bretylium, Moricizine, Ibutilide', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate, Mometasone furoate, Amcinonide, Fluocinolone acetonide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21360, 'Amiodarone', 'Budesonide (nasal)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the systemic bioavailability of budesonide, which undergoes extensive first-pass and systemic metabolism via intestinal and hepatic CYP450 3A4. In pharmacokinetic studies, 6- to 8-fold increases in budesonide systemic exposure (AUC) have been observed during coadministration of the potent CYP450 3A4 inhibitor ketoconazole with different oral formulations of budesonide.', 'DDInter', 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors. If concomitant use cannot be avoided, the dosing times between budesonide and the CYP450 3A4 inhibitor should be separated by as much as possible. In addition, the lowest effective dosage of budesonide should be prescribed, and further adjustments made as necessary according to therapeutic response and tolerance.', 'Metabolism', 'The possibility of increased systemic adverse effects of budesonide should be considered during coadministration with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21375/', '', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate, Mometasone furoate, Amcinonide, Fluocinolone acetonide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21361, 'Amiodarone', 'Bumetanide', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21376/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Propafenone, Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21362, 'Amiodarone', 'Bupivacaine', 'Moderate', 'Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.', 'DDInter', 'Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics. ECG monitoring should be considered.', 'Synergism', 'Patients treated with class III antiarrhythmic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21377/', '', 'Procaine, Chloroprocaine, Tetracaine', 'Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Moricizine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21363, 'Amiodarone', 'Buprenorphine', 'Moderate', 'Buprenorphine administered transdermally at a higher than recommended dosage has been associated with prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval such as amiodarone may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Coadministration with amiodarone may increase the plasma concentrations and pharmacologic effects of buprenorphine. The proposed mechanism is amiodarone inhibition of buprenorphine metabolism via CYP450 3A4. The risk of central nervous system and respiratory depression may be increased.', 'DDInter', 'A dosage of 20 mcg/hr should not be exceeded in patients receiving the buprenorphine transdermal system. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.Pharmacologic response to buprenorphine and vital signs should be monitored more closely whenever a CYP450 3A4 inhibitor such as amiodarone is added to or withdrawn from therapy, and the buprenorphine dosage adjusted as necessary. If clinically significant respiratory depression occurs, buprenorphine should be withdrawn.', 'Metabolism', 'A dosage of 20 mcg/hr should not be exceeded in patients receiving the buprenorphine transdermal system.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21378/', '', 'Diamorphine, Acamprosate, Varenicline, Nalmefene, Nicotine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Opium, More', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21364, 'Amiodarone', 'Cabazitaxel', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cabazitaxel, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised if cabazitaxel is prescribed with CYP450 3A4 inhibitors. Pharmacologic response to cabazitaxel should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the cabazitaxel dosage adjusted as necessary. Regular monitoring of peripheral blood counts between treatment cycles is recommended, and patients should be advised to contact their physician if they experience potential signs and symptoms of cabazitaxel toxicity such as infection, fever, chills, diarrhea, unusual bruising or bleeding, and burning, tingling, or numbness in the hands and feet.', 'Metabolism', 'Caution is advised if cabazitaxel is prescribed with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21379/', '', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Topotecan', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21365, 'Amiodarone', 'Cabozantinib', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21380/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Regorafenib, Copanlisib, Alpelisib, Abemaciclib, Erdafitinib, Neratinib, Trametinib, Capmatinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21366, 'Amiodarone', 'Calaspargase pegol', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', 'DDInter', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21381/', '', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21367, 'Amiodarone', 'Canakinumab', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21382/', '', 'Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21368, 'Amiodarone', 'Cannabidiol', 'Moderate', 'Coadministration of cannabidiol with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cannabidiol causes dose-related elevations of liver transaminases, both alanine aminotransferase (ALT) and aspartate aminotransferase (AST).', 'DDInter', 'Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa. Serum transaminases and total bilirubin levels should be obtained prior to initiating cannabidiol, and patients with elevated baseline transaminase levels above 3 times the ULN accompanied by elevations in bilirubin above 2 times the ULN should be evaluated. Patients who develop clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, jaundice, dark urine) should have serum transaminases and total bilirubin measured promptly, and cannabidiol treatment interrupted or discontinued as appropriate. Cannabidiol should be discontinued in patients with elevations of transaminase levels greater than 3 times the ULN and bilirubin levels greater than 2 times the ULN. Patients with sustained transaminase elevations of greater than 5 times the ULN should also have treatment discontinued. Patients with prolonged elevations of serum transaminases should be evaluated for other possible causes. Also consider dosage adjustment or discontinuation of any coadministered medication that is known to affect the liver.', 'Synergism', 'Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21383/', '', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Tiagabine, Ethotoin, Topiramate, Paramethadione, Methsuximide, Perampanel, Zonisamide, Fenfluramine, Phensuximide, Methylphenobarbital, Phenacemide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21369, 'Amiodarone', 'Capreomycin', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21384/', '', 'Pyrazinamide, Rifamycin, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21370, 'Amiodarone', 'Carbamazepine', 'Major', 'Coadministration with inducers of CYP450 3A4, such as rifamycins and St. John''s wort, may decrease the serum concentrations of amiodarone and its metabolite desethylamiodarone (DEA) and result in therapeutic failure. The proposed mechanism is induction of CYP450 3A4 hepatic metabolism of amiodarone.', 'DDInter', 'Monitoring serum amiodarone and DEA levels and patient''s clinical status is recommended if CYP450 3A4 inducers are added to or deleted from a stable drug regimen that includes amiodarone. Alternative therapy or dosage adjustments may also be considered. Patients should be advised to notify their doctor if they experience worsening of their symptoms (e.g., palpitations or irregular heartbeat).', 'Metabolism', 'Monitoring serum amiodarone and DEA levels and patient''s clinical status is recommended if CYP450 3A4 inducers are added to or deleted from a stable drug regimen that includes amiodarone.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21385/', '', 'Tiagabine, Ethotoin, Topiramate, Paramethadione, Methsuximide, Perampanel, Zonisamide, Fenfluramine, Phensuximide, Methylphenobarbital, Phenacemide, More', 'Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21371, 'Amiodarone', 'Carboplatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21386/', '', 'Pertuzumab, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Aflibercept, Trastuzumab, Hydroxyurea, Talimogene laherparepvec, Estramustine, More', 'Propafenone, Dronedarone, Tocainide, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21372, 'Amiodarone', 'Carfilzomib', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21387/', '', 'Quinidine, Lidocaine, Dronedarone, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, More', 'Pertuzumab, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Aflibercept, Trastuzumab, Hydroxyurea, Talimogene laherparepvec, Estramustine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21373, 'Amiodarone', 'Cariprazine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of cariprazine and its major active metabolite, didesmethyl cariprazine (DDCAR), both of which are primarily metabolized by the isoenzyme. The extent to which other, less potent inhibitors of CYP450 3A4 may interact with cariprazine and its metabolites is unknown.', 'DDInter', 'Caution is advised when cariprazine is prescribed with CYP450 3A4 inhibitors. Patients should be monitored for adverse effects such as extrapyramidal symptoms, cognitive and motor impairment, hyperglycemia, dyslipidemia, weight gain, orthostatic hypotension, leucopenia, neutropenia, seizures and dysphagia, and the dosage of cariprazine adjusted as necessary in accordance with the product labeling.', 'Metabolism', 'Caution is advised when cariprazine is prescribed with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21388/', '', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Brexpiprazole, Loxapine, Molindone, Thiothixene', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21374, 'Amiodarone', 'Carteolol', 'Moderate', 'Additive effects of severe bradycardia, cardiac arrest, and ventricular fibrillation may occur in patients administered amiodarone and beta blockers. The mechanism may be related to additive slowing in AV conduction.', 'DDInter', 'Clinical monitoring of patient hemodynamic status and response is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21389/', '', 'Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Guanethidine, Levobunolol', 'Propafenone, Procainamide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21375, 'Amiodarone', 'Carteolol (ophthalmic)', 'Moderate', 'Additive effects of severe bradycardia, cardiac arrest, and ventricular fibrillation may occur in patients administered amiodarone and beta blockers. The mechanism may be related to additive slowing in AV conduction.', 'DDInter', 'Clinical monitoring of patient hemodynamic status and response is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21390/', '', 'Apraclonidine, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Brimonidine, Guanethidine, Levobunolol', 'Quinidine, Lidocaine, Propafenone, Procainamide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21376, 'Amiodarone', 'Carvedilol', 'Moderate', 'Additive effects of severe bradycardia, cardiac arrest, and ventricular fibrillation may occur in patients administered amiodarone and beta blockers. The mechanism may be related to additive slowing in AV conduction.', 'DDInter', 'Clinical monitoring of patient hemodynamic status and response is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21391/', '', 'Bretylium, Moricizine, Procainamide, Ibutilide', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21377, 'Frangula purshiana bark', 'Amiodarone', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21392/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21378, 'Amiodarone', 'Castor oil', 'Moderate', 'Bowel cleansing as well as overuse of certain laxatives may cause electrolyte loss and increase the risk of torsade de pointes ventricular arrhythmia in patients treated with drugs that prolong the QT interval. Electrolyte disturbances including hypokalemia and hypomagnesemia have been reported with laxative abuse and are known risk factors for torsade de pointes associated with QT interval prolongation.', 'DDInter', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives. The recommended dosage and duration of use should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Patients treated with drugs that prolong the QT interval should exercise caution when self-medicating with laxatives.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21393/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Tegaserod, Plecanatide, Lubiprostone, Methylcellulose, Magnesium oxide, Linaclotide, Naloxone, Magnesium carbonate', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21379, 'Amiodarone', 'Celecoxib', 'Moderate', 'Coadministration with inhibitors of CYP450 2C9 may increase the plasma concentrations of celecoxib, which is primarily metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of celecoxib should be considered.', 'DDInter', 'Clinical monitoring for altered effects of celecoxib is recommended following initiation or discontinuation of a CYP450 2C9 inhibitor. Dosage adjustments may be required if an interaction is suspected. Patients should be advised to notify their physician if they experience potential signs and symptoms of celecoxib toxicity such as abdominal pain, black or tarry stools, nausea, vomiting, lethargy, fluid retention, swelling of legs, and worsening heart failure.', 'Metabolism', 'Clinical monitoring for altered effects of celecoxib is recommended following initiation or discontinuation of a CYP450 2C9 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21394/', '', 'Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Opium, Pentazocine, Dihydrocodeine, Naloxone, Nalbuphine, Fenoprofen, More', 'Tocainide, Dronedarone, Procainamide, Disopyramide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21380, 'Amiodarone', 'Cenobamate', 'Moderate', 'Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates. The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.', 'DDInter', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21395/', '', 'Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Tiagabine, Ethotoin, Topiramate, Paramethadione, Methsuximide, Perampanel, Zonisamide, Fenfluramine, Phensuximide, Methylphenobarbital, Phenacemide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21381, 'Amiodarone', 'Ceritinib', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21396/', '', 'Tocainide, Bretylium, Mexiletine', 'Regorafenib, Copanlisib, Alpelisib, Abemaciclib, Erdafitinib, Neratinib, Trametinib, Capmatinib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21382, 'Amiodarone', 'Cerivastatin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of HMG-CoA reductase inhibitors (i.e., statins) that are metabolized by the isoenzyme. Lovastatin and simvastatin are particularly susceptible because of their low oral bioavailability, but others such as atorvastatin and cerivastatin may also be affected.', 'DDInter', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor. It is advisable to monitor lipid levels and use the lowest effective statin dose. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. Fluvastatin, pravastatin, and rosuvastatin are not expected to interact with CYP450 3A4 inhibitors.', 'Metabolism', 'Caution is recommended if atorvastatin, cerivastatin, lovastatin, simvastatin, or red yeast rice (which contains lovastatin) is prescribed with a CYP450 3A4 inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21397/', '', 'Fenofibric acid, Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Alirocumab', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21383, 'Amiodarone', 'Certolizumab pegol', 'Moderate', 'Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases. Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.', 'DDInter', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids). Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly. The effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21398/', '', 'Tocainide, Dronedarone, Dofetilide, Bretylium, Moricizine, Ibutilide', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21384, 'Amiodarone', 'Cevimeline', 'Moderate', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of cevimeline, which is metabolized by these isoenzymes.', 'DDInter', 'Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to notify their physician if they experience excessive adverse cholinergic effects of cevimeline such as nausea, vomiting, diarrhea, sweating, salivation, urinary frequency, visual disturbance, confusion, tremor, palpitations, or irregular heartbeat.', 'Metabolism', 'Dosage adjustments and clinical monitoring may be appropriate whenever a CYP450 2D6 and/or 3A4 inhibitor is added to or withdrawn from therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21399/', '', 'Bethanechol, Neostigmine, Pyridostigmine, Ambenonium, Pilocarpine', 'Lidocaine, Tocainide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21385, 'Amiodarone', 'Chloramphenicol', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', 'DDInter', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21400/', '', 'Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Neomycin, Tetracycline, Rifamycin, Polymyxin B, More', 'Quinidine, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21386, 'Amiodarone', 'Chlordiazepoxide', 'Minor', 'Amiodarone may increase the pharmacologic effect of benzodiazepines by its adrenergic blocking effects. Data are available for diazepam. Management consists of monitoring the patient''s mental status during coadministration.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21401/', '', 'Meprobamate, Buspirone', 'Quinidine, Propafenone, Dronedarone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21387, 'Amiodarone', 'Chloroquine', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21402/', '', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21388, 'Amiodarone', 'Chlorothiazide', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21403/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21389, 'Amiodarone', 'Chlorpromazine', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21404/', '', 'Brexpiprazole, Loxapine, Molindone, Thiothixene', 'Tocainide, Moricizine, Bretylium', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21390, 'Amiodarone', 'Chlorthalidone', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21405/', '', 'Ascorbic acid, Sulfadiazine, Lactic acid, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, Furazolidone, Oxytetracycline, Zonisamide, More', 'Propafenone, Tocainide, Procainamide, Flecainide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21391, 'Amiodarone', 'Cilostazol', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active metabolites, which are substrates of these isoenzymes. The possibility of prolonged and/or increased pharmacologic effects of cilostazol should be considered.', 'DDInter', 'Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 and/or 2C19 inhibitor is added to or withdrawn from cilostazol therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience adverse effects of cilostazol such as dizziness, nausea, diarrhea, bleeding, or irregular heartbeat.', 'Metabolism', 'Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 and/or 2C19 inhibitor is added to or withdrawn from cilostazol therapy, and the dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21406/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Iloprost, Lepirudin, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21392, 'Amiodarone', 'Cimetidine', 'Moderate', 'Amiodarone serum concentrations may be increased during concomitant therapy with cimetidine and toxicity could result. The mechanism is not known but may involve inhibition of amiodarone hepatic metabolism or of uptake by hepatocytes. Given the long half-life of amiodarone, it may take several weeks for the full effect of the interaction to be realized.', 'DDInter', 'If amiodarone and cimetidine must be used concomitantly, monitoring of amiodarone serum concentrations is recommended.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21407/', '', 'Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan', 'Bretylium, Mexiletine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21393, 'Amiodarone', 'Ciprofloxacin', 'Major', 'Quinolones such as ciprofloxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, and sparfloxacin may cause dose-related prolongation of the QT interval in some patients. Coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction.', 'DDInter', 'Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, as well as bepridil.', 'Synergism', 'Product labeling for certain quinolones recommends avoiding concomitant therapy with class IA (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21408/', '', 'Tetracycline, Cefixime, Tetracycline, Polymyxin B, Chlorhexidine, Neomycin, Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, More', 'Tocainide, Moricizine, Bretylium', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21394, 'Amiodarone', 'Cisapride', 'Major', 'Cisapride can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of cisapride with other drugs that can prolong the QT interval is considered contraindicated.', 'Synergism', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21409/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21395, 'Amiodarone', 'Cisplatin', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Theoretically, coadministration with agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsades de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided. Serum electrolytes should be evaluated and any abnormalities corrected prior to initiating therapy with amiodarone. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsades de pointes such as dizziness, palpitations, or syncope.', 'Synergism', 'Coadministration of amiodarone with medications that can cause potassium and/or magnesium disturbances should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21410/', '', 'Pertuzumab, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Aflibercept, Trastuzumab, Hydroxyurea, Talimogene laherparepvec, Estramustine, More', 'Quinidine, Propafenone, Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21396, 'Amiodarone', 'Citalopram', 'Major', 'Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In addition, central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking citalopram with certain other drugs that cause these effects, especially in elderly or debilitated patients.', 'DDInter', 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval. Citalopram is also not recommended in patients with congenital long QT syndrome, bradycardia, hypokalemia, hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure.', 'Synergism', 'The use of citalopram is not recommended in patients receiving other drugs that prolong the QT interval.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21411/', '', 'Phenelzine, Tranylcypromine, Desvenlafaxine, Isocarboxazid, Oxitriptan, Tryptophan, Vortioxetine, Milnacipran, Levomilnacipran, Esketamine', 'Moricizine, Tocainide, Bretylium, Mexiletine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21397, 'Amiodarone', 'Clarithromycin', 'Major', 'Amiodarone can cause dose-related prolongation of the QT interval. Coadministration with other agents that can prolong the QT interval such as macrolide antibiotics may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). Some macrolides such as clarithromycin, erythromycin, and troleandomycin are also potent inhibitors of CYP450 3A4 and may significantly inhibit the metabolism of amiodarone, which is primarily metabolized by the isoenzyme.', 'DDInter', 'The concurrent use of amiodarone with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if these agents are prescribed together, especially to patients with underlying risk factors. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism, Synergism', 'The concurrent use of amiodarone with other medications that can prolong the QT interval should generally be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21412/', '', 'Tocainide, Moricizine, Bretylium', 'Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Nizatidine, Esomeprazole, Vonoprazan, Dirithromycin, Lincomycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21398, 'Amiodarone', 'Clobazam', 'Moderate', 'Coadministration of clobazam with inhibitors of CYP450 2C19 may significantly increase the plasma concentrations of its active metabolite, N-desmethylclobazam, which is primarily metabolized by the isoenzyme. At therapeutic dosages of clobazam, plasma concentrations of N-desmethylclobazam are 3 to 5 times higher than those of the parent compound.', 'DDInter', 'Dosage adjustment of clobazam may be necessary when coadministered with strong (e.g., fluconazole, fluvoxamine, ticlopidine) or moderate (e.g., omeprazole) inhibitors of CYP450 2C19.', 'Metabolism', 'Dosage adjustment of clobazam may be necessary when coadministered with strong (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21413/', '', 'Meprobamate, Buspirone', 'Quinidine, Tocainide, Dronedarone, Procainamide, Disopyramide, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21399, 'Amiodarone', 'Clofarabine', 'Moderate', 'The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.', 'DDInter', 'Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21414/', '', 'Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Pralatrexate, Decitabine, Azacitidine, Capecitabine', 'Quinidine, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (21400, 'Amiodarone', 'Clofazimine', 'Major', 'Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', 'DDInter', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks. Caution and clinical monitoring are recommended if concomitant use is required. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Coadministration of class IA or class III antiarrhythmic agents with other drugs that can prolong the QT interval should preferably be avoided unless benefits are anticipated to outweigh the risks.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/21415/', '', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', '', 1767369485);
